Sex research is a real field with real findings, mostly drowned out by sensational press releases that overstate small studies. Here's the more honest version: areas of current research that are genuinely interesting, with the hype filtered out. Useful if you want to be informed about where the science is actually pointing.

The clitoral and pelvic anatomy frontier

The clitoris was first comprehensively mapped via medical imaging in 1998 — embarrassingly recent. Research since then has continued to refine the picture:

  • The internal clitoral structure is even more extensive than the original 1998 imaging suggested
  • The neurovascular network connecting clitoris, urethral sponge, and surrounding tissue is more interconnected than separate-structure framings imply
  • The "G-spot" is increasingly understood as the back side of the internal clitoral network rather than a separate structure
  • Pelvic floor muscle imaging during arousal and orgasm continues to refine understanding of orgasm mechanics

What this matters for: the older "vaginal vs clitoral orgasm" framing is functionally obsolete. Current research treats orgasm as a continuum involving multiple stimulation pathways for the same connected anatomical system.

Hormonal contraception and mental health

This has been a contentious area for years. Recent large studies have produced more nuanced findings:

  • Hormonal contraception is associated with modest increases in depression risk, especially in adolescents
  • The effect size is smaller than alarming headlines suggest but real
  • Different formulations have different profiles (drospirenone-containing pills appear gentler on mood than older formulations)
  • Some users have significant mood effects; most don't
  • Switching formulations or methods often resolves issues for users who experience them

What this matters for: the "all hormonal contraception affects mood" framing is wrong; the "no hormonal contraception affects mood" framing is also wrong. Individual variation is real, and individual users should pay attention to their own response.

The ongoing menopause hormone therapy reckoning

The 2002 Women's Health Initiative study famously scared a generation of women off hormone replacement therapy (HRT). Research since has substantially revised that picture:

  • The original study's risk findings applied mostly to older initiation of HRT (women over 60 starting HRT)
  • For women starting HRT during the menopausal transition (45-55), the risk-benefit calculation looks much more favourable
  • Vaginal oestrogen specifically (low-dose, local) has minimal systemic risk and dramatic benefits for genitourinary syndrome of menopause
  • Many women who could benefit from HRT have been dissuaded by outdated risk framings

What this matters for: if you're perimenopausal or postmenopausal and have been told HRT is risky without nuance, the conversation deserves revisiting with an updated clinician.

PrEP advances

HIV pre-exposure prophylaxis continues to develop:

  • Long-acting injectable PrEP (every 2-month injection of cabotegravir) is now available in some markets
  • Lenacapavir (every 6-month injection) showed remarkable efficacy in trials and is rolling out
  • On-demand PrEP (pills taken around specific exposure events rather than daily) has good evidence and growing acceptance
  • Access in South Africa continues to expand, with the public sector providing significant coverage

What this matters for: the daily-pill version of PrEP is no longer the only option. If daily adherence has been a barrier, alternatives exist or are coming.

The microbiome and sexual health

Increasing research attention on the vaginal, oral, and gut microbiomes in sexual health:

  • Vaginal microbiome diversity correlates with infection susceptibility (BV, yeast, STI risk)
  • Specific Lactobacillus species are protective; their absence is a risk factor
  • Probiotic interventions for vaginal health are showing more promise than earlier scepticism suggested
  • Antibiotics' effects on the vaginal microbiome are being better characterised

What this matters for: ongoing recurrent BV or yeast infections may benefit from microbiome-focused approaches in addition to standard antimicrobial treatment.

Pelvic floor research

Pelvic floor physiotherapy is one of the more rapidly-evolving therapeutic areas:

  • Better understanding of hypertonic (too-tight) vs hypotonic (too-loose) pelvic floors and their different treatment needs
  • Recognition that male pelvic floor dysfunction affects erectile function more than previously credited
  • Postpartum pelvic floor work is increasingly evidence-based and delivering better outcomes
  • Pelvic floor specialist services are expanding in major SA cities

What this matters for: pelvic floor symptoms (pain, leakage, sexual difficulty) increasingly have treatment options that didn't exist a decade ago.

The orgasm gap research

The well-documented "orgasm gap" between men and women in heterosexual partnered sex continues to be researched. Findings:

  • The gap closes substantially when clitoral stimulation is included in encounters
  • It closes nearly entirely in same-sex encounters between women
  • It closes in solo sex (where both genders orgasm at similar rates)
  • The gap is smaller in established long-term relationships than in casual encounters
  • It's smaller in egalitarian relationships than traditional ones

The conclusion researchers keep arriving at: the orgasm gap isn't anatomical; it's behavioural and structural. The information is widely available; implementation is patchy.

Trauma-informed sexual care

The intersection of trauma research and sexual health care is one of the more meaningful developments:

  • Better recognition of how trauma affects sexual function physically and behaviourally
  • Polyvagal-informed approaches to sexual difficulties are increasingly mainstream
  • Specific therapies (Somatic Experiencing, sensorimotor psychotherapy) have growing evidence for sexual difficulties with trauma origins
  • Better training for practitioners in trauma-informed sexual health care

What this matters for: sexual difficulties that haven't responded to standard interventions sometimes have trauma components that newer therapeutic approaches address better.

Mental health medication and sexual function

Better characterisation of how psychiatric medications affect sexual function:

  • SSRI sexual side effects are now better quantified (rates higher than originally reported)
  • Bupropion's role in counteracting SSRI sexual side effects is well-established
  • Newer antidepressants (vortioxetine) show better sexual side effect profiles in some studies
  • PSSD (post-SSRI sexual dysfunction) is increasingly recognised as a real entity worth careful management

What this matters for: if you're on antidepressants and have sexual side effects, the conversation with your prescriber has more options than five years ago.

Long Covid and sexual function

An emerging area as the pandemic recedes:

  • Long Covid is associated with reduced libido, fatigue affecting sexual life, and sometimes erectile dysfunction
  • The mechanisms aren't fully understood — vascular, autonomic, hormonal, and inflammatory pathways all implicated
  • Treatment is still being worked out

What this matters for: if your sex life changed after Covid and hasn't recovered, you're not imagining it. The phenomenon is real and is starting to be addressed clinically.

Aging and sexuality

More research, better quality, on adult intimate life past 50:

  • Sexual activity remains common and important for many adults into their 70s and beyond
  • The "sexless older adult" stereotype is wrong for the majority
  • Adaptations (lubricants, vaginal oestrogen, PDE5 inhibitors, position changes) maintain sexual function for most
  • The bigger barrier is usually social isolation and partner availability rather than physical capacity

What to be skeptical of

Some areas where press releases overstate findings:

  • Specific supplements claimed to "boost libido" — usually small studies, weak effects, often industry-funded
  • "Hormone-balancing" interventions without specific clinical claims — usually marketing rather than science
  • "Pheromone" products — pheromone receptors in humans are vestigial; products claiming to use them work via other mechanisms (or don't work)
  • "Quantum" anything in the wellness space — usually marketing dressed in physics terminology

Where to read good information

Sources that provide trustworthy, accessible coverage of sexual research:

  • The Society for Sex Therapy and Research (SSTAR)
  • The International Society for the Study of Women's Sexual Health (ISSWSH)
  • Mayo Clinic, NHS, and similar institutional sources
  • Specific researchers with public communication: Lori Brotto, Justin Lehmiller, Emily Nagoski, others
  • Sex-positive medical professionals on social media (carefully filtered for credentials)

Avoid: anonymous wellness blogs, supplement-company-funded "research," and any source that doesn't link to actual studies.

The bottom line

Sex research is a real field producing real findings. The honest version of the current state is more nuanced than press releases suggest, and more useful than dismissals of the field as too soft to take seriously.

The areas worth watching: clitoral anatomy refinement, hormonal contraception and mental health, menopause and HRT, microbiome research, pelvic floor advances, trauma-informed sexual care, mental health medication interactions, long Covid effects, and aging sexuality.

The areas to be skeptical of: most "boost-your-libido" supplement claims, vague hormonal-balance products, anything with "quantum" or "energy" in the marketing.

Stay curious, read primary sources when you can, and update your understanding when the evidence shifts.